Longboard Pharma Investor & Analyst Event in NY on September 16, 2024

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a biopharmaceutical company in the clinical stage, is devoted to the development of groundbreaking treatments for neurological diseases. They have announced an upcoming Investor & Analyst Event that will provide updates on their global Phase 3 Program for bexicaserin (LP352). This drug, a pioneering 5-HT2C receptor superagonist, is intended for addressing seizures linked to Developmental and Epileptic Encephalopathies (DEEs) in individuals aged two years and older.

The event is scheduled for Monday, September 16, 2024, from 10 AM to noon ET at Cooley LLP, 55 Hudson Yards, New York, NY. It will include contributions from Longboard’s leadership team and significant figures in the DEE domain, such as Dr. Dennis Dlugos from the Children's Hospital of Philadelphia and Ilene Penn Miller, Director of the Rare Epilepsy Network (REN). A live Q&A session will follow the formal presentations. Attendance in person is limited to invited research analysts and institutional investors, but the event can be viewed live or later via an archived webcast on Longboard's website.

Established as a clinical-stage biopharmaceutical company, Longboard Pharmaceuticals is dedicated to creating innovative treatments for neurological conditions. Their focus is on advancing a series of centrally acting product candidates that are highly selective for specific G protein-coupled receptors (GPCRs). These candidates are the result of over 20 years of intensive GPCR research. One of the key drugs in their pipeline is bexicaserin (LP352), an oral 5-HT2C receptor superagonist. Notably, bexicaserin has shown no impact on the 5-HT2B and 5-HT2A receptor subtypes and has received Breakthrough Therapy designation from the FDA for treating seizures associated with DEEs in patients two years and older. Earlier in the year, Longboard shared positive topline results from a Phase 1b/2a clinical trial, known as the PACIFIC Study, which assessed bexicaserin in patients with DEEs.

In addition to bexicaserin, Longboard is making progress with LP659, another oral therapy. LP659 acts on the sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 and is being explored for its potential in treating rare neuroinflammatory conditions. Longboard has recently wrapped up a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Both bexicaserin and LP659 are still investigational compounds and have not yet received marketing approval from the U.S. Food and Drug Administration (FDA) or any other regulatory bodies.